CN114787166A - 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 - Google Patents

噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 Download PDF

Info

Publication number
CN114787166A
CN114787166A CN202080084605.7A CN202080084605A CN114787166A CN 114787166 A CN114787166 A CN 114787166A CN 202080084605 A CN202080084605 A CN 202080084605A CN 114787166 A CN114787166 A CN 114787166A
Authority
CN
China
Prior art keywords
degrees
compound
reaction
preparation
crystal form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202080084605.7A
Other languages
English (en)
Other versions
CN114787166B (zh
Inventor
于娟
陈志亮
王世聪
殷婷婷
简凯丽
郑晓平
江志赶
贺海鹰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Medshine Discovery Inc
Original Assignee
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zhangzhou Pientzehuang Pharmaceutical Co Ltd, Medshine Discovery Inc filed Critical Zhangzhou Pientzehuang Pharmaceutical Co Ltd
Publication of CN114787166A publication Critical patent/CN114787166A/zh
Application granted granted Critical
Publication of CN114787166B publication Critical patent/CN114787166B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一种噻吩并[2,3‑c]哒嗪‑4(1H)‑酮类化合物的晶型及其制备方法，以及在制备作为ACC1和ACC2抑制剂的药物中的应用。
Figure DDA0003677272350000011

Description

PCT国内申请，说明书已公开。

Claims (7)

  1. PCT国内申请，权利要求书已公开。
CN202080084605.7A 2019-12-05 2020-12-04 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用 Active CN114787166B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2019112353721 2019-12-05
CN201911235372 2019-12-05
PCT/CN2020/133897 WO2021110138A1 (zh) 2019-12-05 2020-12-04 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用

Publications (2)

Publication Number Publication Date
CN114787166A true CN114787166A (zh) 2022-07-22
CN114787166B CN114787166B (zh) 2023-09-19

Family

ID=76221503

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080084605.7A Active CN114787166B (zh) 2019-12-05 2020-12-04 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用

Country Status (6)

Country Link
US (1) US11673899B2 (zh)
EP (1) EP4071153B1 (zh)
JP (1) JP7198968B2 (zh)
CN (1) CN114787166B (zh)
ES (1) ES2960703T3 (zh)
WO (1) WO2021110138A1 (zh)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358154A (zh) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
CN105358152A (zh) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
WO2017147161A1 (en) * 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
CN108368125A (zh) * 2015-10-26 2018-08-03 吉利德阿波罗公司 Acc抑制剂及其用途
CN108699078A (zh) * 2016-03-02 2018-10-23 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
CN110382503A (zh) * 2017-03-03 2019-10-25 吉利德科学公司 制备acc抑制剂及其固体形式的方法
CN112218871B (zh) * 2018-06-05 2022-10-18 南京明德新药研发有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2776038T1 (en) 2011-11-11 2018-06-29 Gilead Apollo, Llc ACC INHIBITORS AND THEIR USE
CN105358143B (zh) * 2013-05-10 2019-01-22 吉利德阿波罗公司 Acc抑制剂和其用途

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105358154A (zh) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
CN105358152A (zh) * 2013-05-10 2016-02-24 尼普斯阿波罗有限公司 Acc抑制剂和其用途
CN108368125A (zh) * 2015-10-26 2018-08-03 吉利德阿波罗公司 Acc抑制剂及其用途
WO2017147161A1 (en) * 2016-02-23 2017-08-31 Raju Mohan Treatment of dermatological disorders or conditions
CN108699078A (zh) * 2016-03-02 2018-10-23 吉利德阿波罗公司 噻吩并嘧啶二酮acc抑制剂的固体形式及其制备方法
CN110382503A (zh) * 2017-03-03 2019-10-25 吉利德科学公司 制备acc抑制剂及其固体形式的方法
CN112218871B (zh) * 2018-06-05 2022-10-18 南京明德新药研发有限公司 噻吩并[2,3-c]哒嗪-4(1H)-酮类衍生物及其应用

Also Published As

Publication number Publication date
WO2021110138A1 (zh) 2021-06-10
CN114787166B (zh) 2023-09-19
EP4071153B1 (en) 2023-08-23
JP2022551769A (ja) 2022-12-13
EP4071153A1 (en) 2022-10-12
US11673899B2 (en) 2023-06-13
EP4071153A4 (en) 2022-10-12
ES2960703T3 (es) 2024-03-06
JP7198968B2 (ja) 2023-01-04
US20230070611A1 (en) 2023-03-09

Similar Documents

Publication Publication Date Title
CN108349982B (zh) 作为tlr7激动剂的7-(噻唑-5-基)吡咯并嘧啶化合物
CN107027307B (zh) 一种抗感染化合物
CN109071489A (zh) 吲唑的合成
CN107573330B (zh) 一种托匹司他的制备方法
Song et al. Facile synthesis and antitumor activity of novel 2-trifluoromethylthieno [2, 3-d] pyrimidine derivatives
WO2004108673A2 (en) Inhibitors of papilloma virus
EP3615502B1 (en) Therapeutic compounds and methods
JP7068402B2 (ja) チアゾール誘導体の製造方法
CN111182896A (zh) 脂肪性肝病的治疗剂以及肥胖症的治疗剂
CN114787166A (zh) 噻吩并[2,3-c]哒嗪-4(1H)-酮类化合物的晶型及其制备方法和应用
CN114292226B (zh) 具有异羟肟酸结构的化合物及其制备方法和应用
EP3192792A1 (en) Aminosulfonyl compound, preparation method therefor and use thereof
CN114746426A (zh) 作为acc1和acc2抑制剂的晶型及其制备方法和应用
CN110343088B (zh) 一种基于PARP抑制剂Niraparib的衍生物及其制备方法和应用
CN116888118A (zh) 苯基二氢嘧啶类化合物及其应用
CN111606888B (zh) 吡咯类衍生物及其制备方法与应用
CN110128359B (zh) 一种尿酸转运体1抑制剂的晶体及其制备方法和用途
Shi et al. Synthesis, Crystal Structure, and Antiproliferative Activity of Novel 7-Arylaminopyrazolo [1, 5-a] pyrimidine Derivatives Containing the Hydrazone Moiety
CN109153652A (zh) 1-(芳基甲基)喹唑啉-2,4(1h,3h)-二酮的制备工艺
CN114560845B (zh) 喹啉化合物的晶型ɑ及其制备方法和应用
CA2540021A1 (en) Hcv inhibitors and methods of using them
CN117126146A (zh) 阿片受体激动剂及其制备方法和用途
CN116284018A (zh) 一种呋喃并[2,3-b]喹啉衍生物的制备方法及其应用
CN118026948A (zh) 三联芳环类化合物及其制备方法、药物组合物和应用
KR20240066870A (ko) 고리화첨가 반응과 고리축소 반응의 연속 반응을 이용한 피롤로[1,2-a]퀴놀린의 제조방법

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant